68Ga标记的微胃泌素类似物DOTA-MGS5在晚期甲状腺髓样癌及其他神经内分泌肿瘤患者中的诊断性能
一项在本中心开展的前瞻性1/2a期试点研究(NCT06155994),纳入6例晚期甲状腺髓样癌(MTC)和6例其他神经内分泌肿瘤(NET)患者,比较68Ga-DOTA-MGS5(靶向胆囊收缩素-2受体)PET/CT与参考标准PET/CT的诊断性能。结果显示MTC患者中68Ga-DOTA-MGS5病灶检出率高、摄取与18F-DOPA和68Ga-DOTATOC相当;在支气管肺NET中可能适用,但在胃肠胰NET中价值似乎有限。
要点
- MTC患者中68Ga-DOTA-MGS5 PET/CT病灶摄取与18F-DOPA和68Ga-DOTATOC相当。
- 支气管肺NET患者中68Ga-DOTA-MGS5 PET/CT可能适用,需更大样本验证。
- 胃肠胰NET患者中68Ga-DOTA-MGS5 PET/CT价值似乎有限。
核心结论
- 68Ga-DOTA-MGS5的CCK2R PET/CT在MTC患者中显示高肿瘤病灶检出率,病灶摄取值与18F-DOPA和68Ga-DOTATOC相当。
- 在非MTC的NET患者中,68Ga-DOTA-MGS5 PET/CT在支气管肺NET患者中可能适用,需在更大患者队列中验证。
- 相反,68Ga-DOTA-MGS5 PET/CT在胃肠胰NET患者中似乎价值有限。
研究设计与样本
- 前瞻性1/2a期试点研究(NCT06155994),在本中心开展,比较68Ga-DOTA-MGS5 PET/CT与参考标准PET/CT的诊断性能。
- 纳入6例晚期甲状腺髓样癌(MTC)患者和6例其他神经内分泌肿瘤(NET)患者,其中胃肠胰(GEP)NET 4例、支气管肺(BP)NET 2例。
- 所有患者均有经68Ga-DOTATOC和18F-DOPA PET/CT证实的已知转移灶。
- 比较正常组织和判定为恶性病灶的示踪剂摄取强度(SUVmax/SUVmean)与标准PET显像(病灶数量、每病灶摄取)。
主要发现
- 与标准显像相比,68Ga-DOTA-MGS5显示血池活性显著增高(P ≤ 0.009),注射后2小时病灶对比度较注射后1小时改善。
- 6例MTC患者中4例在68Ga-DOTA-MGS5 PET/CT上病灶为阳性。
- 18F-DOPA检出51个病灶 vs 68Ga-DOTA-MGS5检出48个病灶,68Ga-DOTA-MGS5在注射后1小时和2小时的平均SUVmax为7.2,显著高于18F-DOPA的4.7(P < 0.001)。
- 2例MTC患者同时行68Ga-DOTATOC和68Ga-DOTA-MGS5显像,检出病灶总数相同(n = 14),平均SUVmax分别为24.3 vs 注射后1小时17.4和2小时18.7(P > 0.5)。
- 非MTC NET患者中,2例BP-NET患者确认26个CCK2R阳性病灶,而68Ga-DOTATOC显像45个病灶;4例GEP-NET患者中,68Ga-DOTATOC PET/CT显示阳性摄取的21个病灶中仅1个(回肠NET)被68Ga-DOTA-MGS5显像,其余3例患者病灶在68Ga-DOTA-MGS5 PET/CT上为阴性。
局限性
- 原文结论指出,68Ga-DOTA-MGS5 PET/CT在BP-NET患者中的可能适用性需在更大患者队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A prospective phase 1/2a pilot study (NCT06155994) was performed at our center to compare the diagnostic performance of cholecystokinin-2 receptor (CCK2R) PET/CT imaging with the 68Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH2 (68Ga-DOTA-MGS5) with that of the reference standard PET/CT. Methods: Six patients with advanced medullary thyroid cancer (MTC) and 6 patients with other neuroendocrine tumors (NETs)-4 with gastroenteropancreatic (GEP) NETs and 2 with bronchopulmonary (BP) NETs-were included in the study. All patients had known metastases, documented by 68Ga-DOTATOC and 18F-DOPA PET/CT. Intensity of tracer accumulation (SUVmax/SUVmean) of normal tissue and lesions judged malignant was compared with standard PET imaging (number of lesions, uptake per lesion). Results: When compared with standard imaging, 68Ga-DOTA-MGS5 showed significantly increased blood-pool activity (P ≤ 0.009), with improved lesion contrast at 2 h after injection compared with 1 h after injection. Four of 6 patients with MTC had positive lesions on 68Ga-DOTA-MGS5 PET/CT. Fifty-one lesions were detected with 18F-DOPA versus 48 with 68Ga-DOTA-MGS5, with a significantly higher mean SUVmax of 7.2 at 1 h and 2 h after injection versus 4.7 with 18F-DOPA (P < 0.001). In the 2 patients with MTC imaged with 68Ga-DOTATOC and 68Ga-DOTA-MGS5, the same total number of lesions (n = 14) was detected (mean SUVmax, 24.3 vs. 17.4 and 18.7 at 1 and 2 h after injection, respectively; P > 0.5). In patients with non-MTC NETs, 26 CCK2R-positive lesions were confirmed for 2 patients with BP-NETs compared with 45 lesions visualized with 68Ga-DOTATOC. In the 4 patients with GEP-NETs, only 1 of 21 lesions displaying positive uptake on 68Ga-DOTATOC PET/CT was visualized with 68Ga-DOTA-MGS5 (an ileal NET), whereas the lesions in the other 3 patients were negative on 68Ga-DOTA-MGS5 PET/CT. Conclusion: CCK2R PET/CT using 68Ga-DOTA-MGS5 showed a high tumor lesion detection rate in patients with MTC, with lesion uptake values comparable to those with 18F-DOPA and 68Ga-DOTATOC. In patients with non-MTC NETs, 68Ga-DOTA-MGS5 PET/CT showed possible applicability in patients with BP-NETs, which needs to be verified in a larger patient cohort. In contrast, 68Ga-DOTA-MGS5 PET/CT seemed to be of limited value in patients with GEP-NETs.
引用
- Uprimny C, von Guggenberg E, Sviridenko A, et al. Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors. J Nucl Med. 2025. PMID: 40876951. doi:10.2967/jnumed.125.269863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。